Sun Pharma Advanced Research Company Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 476.9 million compared to INR 252.4 million a year ago. Revenue was INR 584.2 million compared to INR 254.6 million a year ago. Net loss was INR 819.9 million compared to INR 710.5 million a year ago. Basic loss per share from continuing operations was INR 2.55 compared to INR 2.69 a year ago. Diluted loss per share from continuing operations was INR 2.55 compared to INR 2.69 a year ago.
For the full year, sales was INR 2,387.8 million compared to INR 1,372.5 million a year ago. Revenue was INR 2,496.6 million compared to INR 1,440.9 million a year ago. Net loss was INR 2,225.8 million compared to INR 2,034 million a year ago. Basic loss per share from continuing operations was INR 7.82 compared to INR 7.73 a year ago. Diluted loss per share from continuing operations was INR 7.82 compared to INR 7.73 a year ago.